NEWS & EVENTS

Moderna and Catalent today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.

Catalent today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.

Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

Catalent today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.

Catalent today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.

Catalent will continue to put our hearts into making our communities better through our programs promoting diversity & inclusion and corporate responsibility.

Catalent today announced the appointment of Charles Lickfold as Senior Vice President, Chief Information Officer. Mr. Lickfold succeeds John McGill, who plans to retire in September 2020.

Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.

Catalent today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference.